154 related articles for article (PubMed ID: 9557090)
1. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
Switalski M; Kuriga M; Wańkowicz Z
Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
[TBL] [Abstract][Full Text] [Related]
2. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
[TBL] [Abstract][Full Text] [Related]
3. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
7. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
9. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
11. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
12. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
[TBL] [Abstract][Full Text] [Related]
13. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism.
Tan AU; Levine BS; Mazess RB; Kyllo DM; Bishop CW; Knutson JC; Kleinman KS; Coburn JW
Kidney Int; 1997 Jan; 51(1):317-23. PubMed ID: 8995749
[TBL] [Abstract][Full Text] [Related]
14. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
16. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
Djukanović L; Pejanović S; Dragojlović Z; Stosović M
Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD.
Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M
Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842
[TBL] [Abstract][Full Text] [Related]
19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
20. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.
Ljunghall S; Althoff P; Fellström B; Marjanovic B; Nisell J; Weiss L; Wide L
Nephron; 1990; 55(4):380-5. PubMed ID: 2392190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]